• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

50至59岁男性前列腺癌检测率上升的证据:对1995年至2002年间进行的324,684例活检的回顾。

Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002.

作者信息

Lowe Franklin C, Gilbert Scott M, Kahane Hillel

机构信息

Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

出版信息

Urology. 2003 Dec;62(6):1045-9. doi: 10.1016/s0090-4295(03)00782-9.

DOI:10.1016/s0090-4295(03)00782-9
PMID:14665352
Abstract

OBJECTIVES

To analyze the age-specific detection rate of prostate cancer diagnosed from 324,684 biopsies submitted to a single laboratory and to assess the degree of prostate cancer in younger men. The advent of prostate-specific antigen (PSA) testing and increased prostate cancer screening has led to increased evaluations for prostate cancer. The initial stage and age at presentation in prostate cancer has shifted.

METHODS

From 1995 through 2001, all prostate biopsies submitted to the laboratory were reviewed and analyzed for the diagnosis of prostate cancer, cancer detection rate, and age at diagnosis.

RESULTS

The overall detection rate of prostate cancer increased by 15% from 29% to 34% for all biopsies submitted during the study period. For the age group 50 to 59 years, a 45% increase occurred in the detection of prostate cancer from a baseline of approximately 11% in 1995 to greater than 16% in 2001. For the age group 70 to 79 years, the detection of prostate cancer decreased from a baseline of 41% in 1995 to 36% in 2001.

CONCLUSIONS

The increase in prostate cancer diagnosis among younger men in the United States has been significant. The increase is likely multifactorial and may be attributable to the impact of PSA and prostate cancer screening efforts. This has led to a greater number of younger men undergoing evaluation for prostate cancer. Thus, a heightened awareness regarding the diagnosis of prostate cancer among younger men is needed.

摘要

目的

分析提交至单个实验室的324,684份活检样本中前列腺癌的年龄特异性检出率,并评估年轻男性前列腺癌的严重程度。前列腺特异性抗原(PSA)检测的出现以及前列腺癌筛查的增加导致了对前列腺癌评估的增加。前列腺癌的初始阶段和就诊年龄已经发生了变化。

方法

对1995年至2001年间提交至该实验室的所有前列腺活检样本进行回顾和分析,以诊断前列腺癌、癌症检出率和诊断年龄。

结果

在研究期间提交的所有活检样本中,前列腺癌的总体检出率从29%上升至34%,增长了15%。对于50至59岁年龄组,前列腺癌的检出率从1995年约11%的基线水平增长至2001年的超过16%,增长了45%。对于70至79岁年龄组,前列腺癌的检出率从1995年41%的基线水平降至2001年的36%。

结论

美国年轻男性中前列腺癌诊断的增加幅度显著。这种增加可能是多因素的,可能归因于PSA的影响和前列腺癌筛查工作。这导致更多年轻男性接受前列腺癌评估。因此,需要提高对年轻男性前列腺癌诊断的认识。

相似文献

1
Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002.50至59岁男性前列腺癌检测率上升的证据:对1995年至2002年间进行的324,684例活检的回顾。
Urology. 2003 Dec;62(6):1045-9. doi: 10.1016/s0090-4295(03)00782-9.
2
[Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].[在希洪(阿斯图里亚斯)第4医疗区使用前列腺特异性抗原(PSA)的利弊]
Arch Esp Urol. 2005 Jun;58(5):403-11. doi: 10.4321/s0004-06142005000500004.
3
Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.血清前列腺特异性抗原检测前后各时期前列腺癌诊断的发病率。
JAMA. 1995 Nov 8;274(18):1445-9.
4
Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.欧洲前列腺癌筛查随机研究鹿特丹分部中前列腺特异性抗原的变化
Urology. 2004 Feb;63(2):316-20. doi: 10.1016/j.urology.2003.09.028.
5
Natural history of PSA increase with and without prostate cancer.
Urology. 2003 Jul;62(1):64-9. doi: 10.1016/s0090-4295(03)00135-3.
6
Prostate cancer screening in Tyrol, Austria: experience and results.奥地利蒂罗尔州的前列腺癌筛查:经验与结果
Eur Urol. 1999;35(5-6):523-38. doi: 10.1159/000019893.
7
Normal range prostate-specific antigen versus age-specific prostate-specific antigen in screening prostate adenocarcinoma.前列腺腺癌筛查中正常范围前列腺特异性抗原与年龄特异性前列腺特异性抗原的比较
Urology. 1995 Aug;46(2):200-4. doi: 10.1016/s0090-4295(99)80194-0.
8
Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).在基于人群的筛查中,前列腺特异性抗原水平为1.0 ng/mL或更低的男性是否需要进行额外检测?(欧洲前列腺癌筛查随机对照试验,鹿特丹部分)
Urology. 2005 Feb;65(2):343-6. doi: 10.1016/j.urology.2004.09.046.
9
Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?前列腺癌的前列腺特异性抗原检测:是否会耗尽有限的易感个体群体?
Eur J Epidemiol. 2017 Jun;32(6):511-520. doi: 10.1007/s10654-016-0185-z. Epub 2016 Jul 18.
10
American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.美国泌尿外科学会 (AUA) 前列腺癌检测指南:流程和原理。
BJU Int. 2013 Sep;112(5):543-7. doi: 10.1111/bju.12318.

引用本文的文献

1
Low reduction of prostate volume is a significant predictor of prostate cancer at subsequent biopsy in patients with dutasteride: A retrospective study.度他雄胺治疗患者前列腺体积缩小率低是后续前列腺活检中前列腺癌的显著预测因子:一项回顾性研究。
Andrologia. 2020 Dec;52(11):e13810. doi: 10.1111/and.13810. Epub 2020 Aug 20.
2
Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy.提高印度有症状男性前列腺特异性抗原(PSA)活检的临界值以减少不必要的活检。
Indian J Med Res. 2014 Jun;139(6):851-6.
3
Treatment decision-making for localized prostate cancer: what younger men choose and why.
局限性前列腺癌的治疗决策:年轻男性的选择及原因。
Prostate. 2012 Jan;72(1):58-64. doi: 10.1002/pros.21406. Epub 2011 Apr 25.